Pfizer Inc. $PFE Shares Bought by Generali Investments CEE investicni spolecnost a.s.

Key Points

• Generali Investments CEE increased its stake in Pfizer by 76.4% in Q3, buying an additional 47,319 shares to hold 109,269 shares worth about $2.784 million.
• Pfizer declared a quarterly dividend of $0.43 (annualized $1.72), implying a 6.8% yield with an ex-dividend date of Jan. 23 and a payout ratio of 100%.
• Analyst sentiment is mixed after Pfizer set FY2025 guidance of 3.000–3.150 EPS; the stock carries an average broker rating of Hold with an average target of $28.06 and some downgrades following a muted outlook.

Generali Investments CEE investicni spolecnost a.s. raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 76.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 109,269 shares of the biopharmaceutical company's stock after buying an additional 47,319 shares during the quarter. Generali Investments CEE investicni spolecnost a.s.'s holdings in Pfizer were worth $2,784,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PFE. Vanguard Group Inc. raised its position in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company's stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC increased its stake in Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company's stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares in the last quarter. Norges Bank purchased a new position in shares of Pfizer in the second quarter worth $2,270,157,000. Amundi lifted its stake in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company's stock valued at $1,191,760,000 after buying an additional 1,135,457 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.6%

Pfizer stock opened at $25.19 on Monday. The business's 50-day moving average price is $25.10 and its 200 day moving average price is $24.85. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $143.22 billion, a price-to-earnings ratio of 14.65 and a beta of 0.46. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, January 23rd. Pfizer's dividend payout ratio (DPR) is currently 100.00%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Scotiabank assumed coverage on Pfizer in a report on Thursday, November 13th. They set a "sector outperform" rating and a $30.00 target price for the company. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an "underperform" rating in a report on Wednesday. Finally, Citigroup began coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a "neutral" rating and a $26.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $28.06.

Key Stores Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank reaffirmed a Buy on PFE, signaling continued analyst conviction from some firms despite the weak outlook. Scotiabank Reaffirms Buy
• Positive Sentiment: Pfizer moved to strengthen its obesity pipeline by licensing a weight-loss drug from Fosun, a strategic push into a high-growth market that could drive medium-term revenue upside if commercialization succeeds. Pfizer licenses weight-loss drug from Fosun
• Positive Sentiment: New liver cancer trial update suggests potential longer-term oncology upside, adding to the narrative that successful Phase III execution could materially re-rate the stock over time. Pfizer’s New Liver Cancer Trial
• Neutral Sentiment: Analysts and industry write-ups (MarketBeat, Benzinga comparisons, and Motley Fool pieces) are weighing PFE versus peers (Merck, Eli Lilly) — useful context but varied conclusions; these pieces emphasize that Pfizer’s future returns hinge on pipeline execution and commercial recovery. Better Buy in 2026: Pfizer or Merck?
• Neutral Sentiment: One analyst summary notes PFE looks materially undervalued with a high forward yield, but warns upside is conditional on successful late‑stage trials and commercialization. This frames PFE as a yield/turnaround play rather than immediate growth. Pfizer Isn't Dead Money
• Negative Sentiment: Pfizer issued a muted 2026 outlook and trimmed profit guidance, citing lower COVID sales and patent/exclusivity pressures; that guidance and the revenue/profit trims are the primary reasons shares fell today. Pfizer Down After Muted 2026 Outlook
• Negative Sentiment: Following the outlook, some brokers cut or softened ratings (average brokerage rating now around Hold), and the stock has taken analyst downgrades and short‑term selling pressure. Average Rating of Hold from Brokerages
• Negative Sentiment: High-profile commentary (Jim Cramer) highlighting management struggles adds to negative sentiment and short-term headline risk after the guidance release. Jim Cramer: CEO Struggling

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.